Tests levetiracetam and head position for suspected stroke in ambulances
Tests an early ambulance drug and head position in adults with suspected stroke.
Plain-language title generated from the registry record
Registry title: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial
Key facts
- Where
- Shanghai and Suzhou, ChinaSee the 2 sites
- Phase
- Phase 3
Where in China
- Shanghai East HospitalShanghai, ChinaTaking people
- Si County People's HospitalSuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT06773364
- Record updated
- 22 May 2025
- Original description
This is an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. EAST aims to evaluate the effects of pre-hospital levetiracetam and different head positions initiated in ambulance settings on the functional outcome of participants assessed at 90 days.Read full original descriptionShow less
An Investigator Initiated and Conducted, Prospective, Multicentre, Randomised Outcome-blinded Study of Pre-hospital Initiated Levetiracetam and Headposition in Patients With Presumed Acute Stroke
This is an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. EAST aims to evaluate the effects of pre-hospital levetiracetam and different head positions initiated in ambulance settings on the functional outcome of participants assessed at 90 days.
Inclusion: Adults (age ≥18 years); Acute condition that is presumed due to acute stroke, defined on the FAST (Face, Arm, Speech, Time) screen (score ≥2 with an arm deficit); Time ≤2 hours from last seen well; Able to provide brief consent (if a waver of consent not approved by ethics committee).
Exclusion: severe co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability [needing help with everyday activities]); history of epilepsy or seizure at onset; clear indications or contraindications (allergies) for levetiracetam; hypoglycaemia (glucose <2.8mmol/L); coma (no response to painful stimulation); recent head injury; lactating women; clear indications for a particular head position or situations where either head position cannot be maintained (such as severe vomiting and inability to lie down, severe obesity with fatigue and difficulty sitting up, etc.).